BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the second quarter and six months ended June 29, 2008. Consolidated revenue for the quarter was $15.9 million, an increase of 2% from the 2007 period. Revenue in the Company’s surgical products segment increased 19% in the second quarter of 2008 over the 2007 period, while brachytherapy segment revenue decreased 12%. For the first half of the year, consolidated revenue was $31.1 million, an increase of less than 1% over 2007. Surgical products revenue increased 13% over the first half of 2007, while brachytherapy revenue decreased 10%.
